CA-ARIBIO
5.1.2023 13:10:39 CET | Business Wire | Press release
AriBio USA, a clinical-stage biopharmaceutical company, announced the enrollment of their first participants in their Phase 3 trial to evaluate the efficacy of AR1001 in participants with early Alzheimer’s Disease (AD). AR1001 is a blood-brain barrier penetrating small molecule known to inhibit neuron apoptosis and promote neurogenesis, increase neuroplasticity and increase autophagy activity to remove toxic proteins.
This study is a randomized, placebo-controlled, double-blind, multi-center Phase 3 trial that plans to enroll 800 participants from approximately 75 sites for 12 months of treatment, followed by an optional two-year extension phase. Patients will be randomly assigned to receive either 30 mg of AR1001 or placebo once daily for 52 weeks. In the optional-extension study, participants originally assigned to placebo will receive 30 mg of AR1001 for an additional two years of treatment. The primary endpoint in the trial is the Change in the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) at Week 52. “As we learn more about Alzheimer’s disease with the understanding that different therapeutic approaches are necessary to demonstrate a meaningful benefit to patients and their caregivers we look forward to data on AR1001,” said Dr. Greeley, CMO for AriBio USA.
“AriBio USA is excited to share this significant milestone, and we look forward to providing regular updates to the program as enrollment progresses in this Phase 3 trial. We continue to engage with interested investigators and sites who are committed to making a difference in the treatment and care of patients with Alzheimer’s disease,” said James Rock, CEO of AriBio USA, Inc. Enrollment is expected to require approximately 2 years for this Phase 3 trial. Dr. Greeley stated, “As we understand more about Alzheimer’s disease, with the understanding that different therapeutics and lifestyle approaches will be necessary to demonstrate a meaningful benefit to patients and their caregivers, we expect AR1001 to be part of this treatment paradigm.”
AriBio Ltd, the parent company of AriBio USA, is committed to developing new therapeutics in the neurology space with a pipeline of PDE-5 inhibitors and other new molecular entities. “Our goal is to transform the treatment options available for patients with dementia to improve their daily lives,” stated Dr. Matthew Choung, CEO of AriBio Ltd.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on the development of therapies for neurodegenerative diseases. AriBio USA, INC. is the subsidiary company of AriBio Co., Ltd. based in San Diego, CA in charge of clinical operations and regulatory affairs for AriBio.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005102/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Accertify's Q2 Global Air Travel Fraud Report Finds Fraud Pressure Intensifying Across Middle East and Africa15.7.2026 13:00:00 CEST | Press release
Analysis of nearly 133 million airline booking transactions finds bookings departing from Cairo carried the world's highest fraud rate this quarter, while departure cities across the United States and Australia posted among the lowest fraud rates Accertify, a leading fraud decisioning provider whose Predictive Yes Platform helps merchants say yes to more good customers, more revenue, and more growth, today announced the release of its Global Air Travel Fraud Report: Q2 2026, a quarterly analysis examining how fraud pressure varies across global airline markets based on departure city at time of booking. Based on analysis of 132.9 million airline booking transactions processed between April and June 2026, the report evaluates prevented fraud rates across 537 departure cities that each processed at least 10,000 transactions during the quarter, providing airlines with a data-driven view of where Accertify's Predictive Yes platform intervened most frequently at booking. The Q2 findings rev
Forrester’s 2027 Budget Planning Guides: After A Year Of Caution, Business And Tech Leaders Are Ready To Invest Again15.7.2026 11:00:00 CEST | Press release
While leaders are betting on growth, in the age of AI, spending more is no longer enough According to Forrester’s (Nasdaq: FORR) 2027 Budget Planning Guides, business and technology leaders are approaching 2027 with renewed confidence as they increasingly accept volatility as a permanent feature of the business environment. After a year of more cautious spending, more than 80% of leaders expect their budgets to increase over the next 12 months, with as many as one-quarter anticipating growth of 10% or more. But planning in the age of AI demands more than bigger budgets: Increasing investment without modernizing operating models, strengthening data foundations, and improving AI readiness will only accelerate fragmented data, duplicated work, and technical debt. To realize AI’s full potential, leaders must rethink their strategies and prioritize investments in operational foundations, governance, and experimentation that drive tangible outcomes. This year, optimism is widespread across f
Post-Quantum’s Algorithm - Classic McEliece - Achieves Global ISO Standardization to Protect the World From Quantum Cyber Attack15.7.2026 10:00:00 CEST | Press release
Ultra-secure encryption algorithm added to ISO standard for Asymmetric Ciphers Classic McEliece is first PQC algorithm to achieve global standardization Organisations in 177 ISO member states can now adopt Classic McEliece to remain secure from attack by both classical and quantum computers Governments including Germany and the Netherlands already recommend the highly secure Classic McEliece algorithm due to its unmatched security credentials It’s proven that today’s encryption is vulnerable to attack by a sufficiently mature quantum computer running Shor’s algorithm - a catastrophic event commonly known as Q-Day. Even before such a cryptographically relevant quantum computer emerges it is known that adversaries are stealing encrypted data now, which can be decrypted later - also known as Harvest Now, Decrypt Later (HNDL). Google’s recent use of Artificial Intelligence (AI) to optimise Shor’s algorithm reduces the number of physical qubits required to break today’s encryption, therefor
Thredd Joins The Visa Agentic Ready Programme, Bringing Agent Network Readiness To Issuers Across Europe, Starting With Zilch15.7.2026 09:00:00 CEST | Press release
Thredd, the AI-first issuer processing platform, today announced it has joined the Visa Agentic Ready programme, enabling issuers across Europe to participate in agent-initiated payments without rebuilding their payments infrastructure. Consumer payments platform Zilch will be among the first issuers on the platform to enable agent-initiated payments for its cardholders. As a processor and enabler, Thredd sits at the trust layer of the payments ecosystem. By joining the programme, Thredd is ready to support Visa and its clients as the market moves into agentic commerce. Agentic commerce introduces a new type of payment initiator: An AI agent acting on a cardholder's behalf. The core payments principles do not change. Cardholder permission, issuer approval, authentication and fraud monitoring all still apply. What changes is how trust is established and enforced at the point an agent transacts. Taking a Zilch customer as an example, a cardholder might ask an AI agent to find a product w
Surgerii Robotics Announces First European Installation of the SHURUI® Single-Port Surgical System at Vall d'Hebron University Hospital15.7.2026 09:00:00 CEST | Press release
Surgerii Robotics today announced the first European installation of its SHURUI Single-Port (SP) Surgical System at Vall d'Hebron University Hospital in Barcelona, Spain, one of Europe's leading academic medical centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713209503/en/ The first pediatric procedure performed with the SHURUI SP system was a nephroureterectomy on a twelve-year-old boy whose kidney and ureter had become infected and non-functional due to multiple stones. The SHURUI SP system is CE-marked for adult and pediatric use, making it the only CE-marked single-port robotic surgical system currently indicated for pediatric procedures in Europe. The installation marks an important milestone in the international expansion of Surgerii Robotics and the introduction of the technology into a major European reference center. As part of this collaboration, Vall d'Hebron University Hospital has become the first hos
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom